I Don’t Know of a Bigger Story in the World Right Now than Ivermectin: NY Times Best-Selling Author
Posted on 25 May 2021 by Nick Corbishley on Naked Capitalism
Michael Capuzzo, a New York Times best-selling author, has just published an article titled "The Drug That Cracked Covid". The 15-page article chronicles the gargantuan struggle being waged by frontline doctors on all continents to get ivermectin approved as a Covid-19 treatment, as well as the tireless efforts by reporters, media outlets and social media companies to thwart them.
Because of ivermectin, Capuzzo says, there are "hundreds of thousands, actually millions, of people around the world, from Uttar Pradesh in India to Peru to Brazil, who are living and not dying." Yet media outlets have done all they can to "debunk" the notion that ivermectin may serve as an effective, easily accessible and affordable treatment for Covid-19. They have parroted the arguments laid out by health regulators around the world that there just isn't enough evidence to justify its use...
There are three possible explanations for health regulators' refusal to allow the use of a highly promising, well-tolerated off-label medicine such as ivermectin:
- As a generic, ivermectin is cheap and widely available, which means there would be a lot less money to be made by Big Pharma if it became the go-to early-stage treatment against covid.
- Other pharmaceutical companies are developing their own novel treatments for Covid-19 which would have to compete directly with ivermectin. They include ivermectin's original manufacturer, Merck, which has an antiviral compound, molnupiravir, in Phase 3 clinical trials for COVID-19. That might explain the company's recent statement claiming that there is "no scientific basis whatsoever for a potential therapeutic effect of ivermectin against COVID-19.
- If approved as a covid-19 treatment, ivermectin could even threaten the emergency use authorisation granted to covid-19 vaccines. One of the basic conditions for the emergency use authorisation granted to the vaccines currently being used against covid is that there are no alternative treatments available for the disease. As such, if ivermectin or some other promising medicine such as fluvoxamine were approved as an effective early treatment for Covid-19, the vaccines could be stripped of authorisation.
This may explain why affordable, readily available and minimally toxic drugs are not repurposed for use against Covid despite the growing mountains of evidence supporting their efficacy.
Ivermectin has already been approved as a covid-19 treatment in more than 20 countries. They include Mexico where the mayor of Mexico City, Claudia Scheinbaum, recently said that the medicine had reduced hospitalisations by as much as 76%. As of last week, 135,000 of the city's residents had been treated with the medicine. The government of India - the world's second most populous country and one of the world's biggest manufacturers of medicines - has also recommended the use of ivermectin as an early outpatient treatment against covid-19, in direct contravention of WHO's own advice.
Dr Vikas P. Sukhatme, the dean of Emory School of Medicine, recently wrote in a column for the Times of India that deploying drugs such as ivermectin and fluvoxamine in India is likely to "rapidly reduce the number of COVID-19 patients, reduce the number requiring hospitalization, supplemental oxygen and intensive care and improve outcomes in hospitalized patients."
Four weeks after the government included ivermectin and budesonide among its early treatment guidelines, the country has recorded its lowest case count in 40 days.
In many of India's regions the case numbers are plunging in almost vertical fashion. In the capital Delhi, as in Mexico City, hospitalisations have plummeted. In the space of 10 days ICU occupancy fell from 99% to 70%. Deaths are also falling. The test positivity ratio slumped from 35% to 5% in just one month.